New Zealand markets closed

Qiagen N.V. (QGEN)

NYSE - NYSE Delayed price. Currency in USD
Add to watchlist
42.79-0.41 (-0.95%)
At close: 04:00PM EST
42.79 0.00 (0.00%)
After hours: 06:03PM EST

Qiagen N.V.

Hulsterweg 82
Venlo 5912 PL
31 77 355 6600

IndustryDiagnostics & Research
Full-time employees6,000

Key executives

NameTitlePayExercisedYear born
Mr. Thierry BernardCEO, MD & Member of Management Board2.67MN/A1966
Dr. Roland SackersCFO, MD & Member of Management Board1.33MN/A1969
Mr. Antonio SantosSenior VP & Head of Global OperationsN/AN/AN/A
Mr. John GilardiVice President of Corporate Communications & Investor RelationsN/AN/AN/A
Ms. Stephany FosterSenior VP & Head of Human ResourcesN/AN/A1979
Dr. Thomas SchweinsSenior Vice President of Life Science Business AreaN/AN/AN/A
Dr. Thomas TheuringerSenior Director & Head of External CommunicationsN/AN/AN/A
Mr. Jean-Pascal ViolaSenior VP & Head of Molecular Diagnostics Business AreaN/AN/AN/A
Dr. Jonathan G. Sheldon Ph.D.Senior Vice President of Qiagen Digital Insights Business AreaN/AN/A1972
Mr. Thomas NeidertVice President of Global TreasuryN/AN/AN/A
Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories. It also provides interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; assays for prenatal testing and detection of sexually transmitted diseases and HPV, as well as assays for analysis of genomic variants, such as mutations, insertions, deletions, and fusions; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. In addition, it offers PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping, and gene regulation instruments and technologies; human ID and forensics assay consumables, including STR assays for human ID, and assays for food contamination; PCR instruments consist of digital PCR solutions; and developed and configured OEM consumables. Further, the company provides predefined and custom NGS gene panels, library prep kits and components, and whole genome amplification; QIAGEN consumables and instruments, as well as bioinformatics solutions; and custom laboratory and genomic services. It serves molecular diagnostics, academia, pharmaceutical, and applied testing customers. The company was founded in 1986 and is headquartered in Venlo, the Netherlands.

Corporate governance

Qiagen N.V.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.